title: Emtricitabine compared with lamivudine may preserve future therapeutic options in HIV-1-infected children.
authors.affiliation: EA 3620, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Frange
authors.forename: Stephane
authors.initials: S
authors.lastname: Blanche
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Chaix
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D000068679:Emtricitabine; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D007223:Infant; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D003841:Deoxycytidine; D019259:Lamivudine; D000068679:Emtricitabine
keywords: HIV; emtricitabine; lamivudine